ClinicalTrials.gg
CompletedNCT03292406CTCLUpdated Apr 8, 2021Results posted

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

A Phase 2 interventional study of Placebo and CD11301 0.03% in Cutaneous T Cell Lymphoma, sponsored by Galderma R&D. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States — 33 open to participants now, 45 under way, none of them phase 3. Lymphoma, T-Cell, Cutaneous · United States.

Enrollment
52nd of 334
86 · median 33
Started
2017
with 11 others
Phase 2
114 of 434
10 open now
Registered
376th of 434
by date

Among the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, this one is the 52nd largest by enrollment of the 334 interventional ones that give a count, is one of 12 that started in 2017, is one of 114 in phase 2, and was the 376th registered.

Lymphoma, T-Cell, Cutaneous

554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.

Browse Lymphoma, T-Cell, Cutaneous studies →

Open to participants now

33 of the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Lymphoma, T-Cell, Cutaneous studies recruiting now, 33 (75%) set no upper age limit and 6 (14%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, or all of them as a file.
02

Study summary

To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).

Read the detailed description

To assess the efficacy and safety of two concentrations (0.03% and 0.06%) of CD11301 gel in the treatment of early stage CTCL (stage IA, IB, or IIA) versus placebo.

03

Conditions studied

  • Cutaneous T Cell Lymphoma

Keywords

  • T-Cell
  • Lymphoma
  • Cutaneous
  • CTCL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical Diagnosis of CTCL stage IA, IB, or IIA with within last 3 months
  • Have BSA involvement corresponding to stages IA, IB or IIA CTCL with at least 3 distinct lesions

Exclusion criteria

Exclusion Criteria:

  • CTCL that is stage IIB or great or stage IIA with stage N2 with >5% circulating Sezary cells or CD8+ or large cell transformation or Progressive CTCL
  • History of disease
  • Laboratory test values at screening outside of the normal range and judged by the investigator
  • Current participation in another clinical trial of a drug or device or past participation within 4 weeks before Baseline or participant is in exclusion period from a previous clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    CD11301 Gel 0.06%

    Participants applied 0.06% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.

    Drug: CD11301 0.06%

  • Experimental
    CD11301 Gel 0.03%

    Participants applied 0.03% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.

    Drug: CD11301 0.03%

  • Experimental
    Placebo

    Participants applied placebo gel during cycle one followed by 0.03% CD11301 gel topically during cycle two once daily, 3 to 5 times per week, for 24 weeks.

    Drug: Placebo · Drug: CD11301 0.03%

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12

    Overall response is defined as the number of participants that achieved a complete response (CR) or partial response (PR) as assessed by mCAILS. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity. Complete response is defined as a 100% decrease from baseline i.e. score of '0' on the mCAILS scale. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline.

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12

    OR is defined as the number of participants that achieved a complete response or partial response as assessed by mSWAT. mSWAT composite score involved the direct assessment of the BSA of each type of lesion (palm plus fingers of the participant= approximately 1% BSA) in each of 12 areas (Head, Neck, Anterior trunk, Arms, Forearms, Hands, Posterior trunk, Buttocks, Thighs, Legs, Feet, Groin) of the body, multiplying the sum of the BSA of each lesion type by a weighting factor (patch = 1, plaque = 2, and tumor = 3 or 4) and generating a sum of the subtotals of each lesion subtype. mSWAT score (0=no lesions; 400= lesions covering all areas). Complete response is defined as a 100% decrease from baseline. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline, and with a tumor subscore of zero (no tumor).

    Time frame: Week 12

  2. Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score

    Time to overall response (CR or PR) is the number of days from the start of drug application to the first documentation of objective response assessed by mCAILS Score. The 25th, 50th, and 75th percentiles were presented along with 95% confidence intervals using the log-log transformation. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.

    Time frame: Up to Week 36

  3. Duration of Overall Response (Complete Response or Partial Response) Based on mCAILS Score

    The duration of overall response (complete or partial) of the target treated lesions based on the mCAILS score was calculated in days as: (date of first non-response after responding) - (date of response) + 1. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.

    Time frame: Up to Week 36

  4. Time to Progressive Disease Using mSWAT

    Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, Nadir is defined as the lowest skin score (best response).

    Time frame: Up to Week 36

  5. Change From Baseline in Skindex-29 Survey Results at Week 12, 24 and 36

    Participants answered 30 questions as part of the Skindex-29 survey. A composite score and 3 sub scores were calculated from the results. Item 18 of the survey was not used in any scoring. First, answers to each item were given a numeric value: Never = 0; Rarely = 25; Sometimes = 50; Often = 75; All the time = 100. The items used to calculate each subscore were: Emotions: 3, 6, 9, 12, 13, 15, 21, 23, 26, and 28 (10 items), Symptoms: 1, 7, 10, 16, 19, 24, and 27 (7 items), Functioning: 2, 4, 5, 8, 11, 14, 17, 20, 22, 25, 29, and 30 (12 items). The composite score is the average of the 3 sub scores ranging from 0 (no effect)-100 (maximum effect), higher score corresponds to lower quality of life.

    Time frame: Week 12, 24 and Follow up (Week 36)

07

Results

Posted Apr 8, 2021

Participant flow

This study was conducted at 3 countries (France, Germany, USA) between 19 Dec 2017 to 17 Mar 2020. A total of 86 participants were randomized to 1 of the 3 treatment groups (placebo gel or CD11301 gel 0.03% or 0.06%) in a 1:1:1 ratio.

Participant flow — Overall Study
MilestoneCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
Started302828
Participants treated302827
Completed171515
Not completed131313
Withdrew: Progressive disease634
Withdrew: Adverse event714
Withdrew: Withdrawal by subject072
Withdrew: Protocol violation011
Withdrew: Other012

Outcome measures

PrimaryNumber of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12

Overall response is defined as the number of participants that achieved a complete response (CR) or partial response (PR) as assessed by mCAILS. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity. Complete response is defined as a 100% decrease from baseline i.e. score of '0' on the mCAILS scale. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Reported Overall Response (Complete and Partial) of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score at Week 12
ParticipantsCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
Complete Response020
Partial Response451
SecondaryNumber of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12

OR is defined as the number of participants that achieved a complete response or partial response as assessed by mSWAT. mSWAT composite score involved the direct assessment of the BSA of each type of lesion (palm plus fingers of the participant= approximately 1% BSA) in each of 12 areas (Head, Neck, Anterior trunk, Arms, Forearms, Hands, Posterior trunk, Buttocks, Thighs, Legs, Feet, Groin) of the body, multiplying the sum of the BSA of each lesion type by a weighting factor (patch = 1, plaque = 2, and tumor = 3 or 4) and generating a sum of the subtotals of each lesion subtype. mSWAT score (0=no lesions; 400= lesions covering all areas). Complete response is defined as a 100% decrease from baseline. Partial response is defined as at least a 50%, but less than 100%, decrease from baseline, and with a tumor subscore of zero (no tumor).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Reported Overall Response (OR) of Target Treated Lesions Based on Modified Severity-Weighted Assessment Tool (mSWAT) Score at Week 12
ParticipantsCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
Complete Response000
Partial Response642
SecondaryTime to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score

Time to overall response (CR or PR) is the number of days from the start of drug application to the first documentation of objective response assessed by mCAILS Score. The 25th, 50th, and 75th percentiles were presented along with 95% confidence intervals using the log-log transformation. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.

Time frame:
Up to Week 36
Reported as:
Number · Days
Time to Participant's First Overall Response (Complete or Partial) of the Target Treated Lesions Based on the mCAILS Score
DaysCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
25th (95% CI)169 (84.0 to 169.0)85 (83.0 to 174.0)NA (85.0 to NA)
50th (95% CI)197 (169.0 to 257)NA (169.0 to NA)NA (NA to NA)
75th (95% CI)257 (197.0 to 257)NA (NA to NA)NA (NA to NA)
SecondaryDuration of Overall Response (Complete Response or Partial Response) Based on mCAILS Score

The duration of overall response (complete or partial) of the target treated lesions based on the mCAILS score was calculated in days as: (date of first non-response after responding) - (date of response) + 1. The mCAILS assessment total was derived from components collected on the case report form (CRF). Target treated lesions (1-5 lesions) were rated in erythema (0-8, where 0=no evidence and 8= very severe), scaling (0-8, where 0=no evidence and 8= very severe), plaque elevation (0-3, where 0=no evidence and 3= marked elevation), and size (scale=0-18, where 0= no measurable area and 18= size of lesion \>300 centimeter \[cm\]\^2). These 4 ratings were summed to create subtotals, 1 per lesion. The final mCAILS assessment score was the sum of these subtotals. Total summation Score: 0-50 where higher score indicated higher severity.

Time frame:
Up to Week 36
Reported as:
Number · Days
Duration of Overall Response (Complete Response or Partial Response) Based on mCAILS Score
DaysCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
25th (95% CI)133 (29.0 to 141.0)NA (38.0 to NA)NA (NA to NA)
50th (95% CI)141 (133.0 to NA)NA (38.0 to NA)NA (NA to NA)
75th (95% CI)NA (133.0 to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Progressive Disease Using mSWAT

Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, Nadir is defined as the lowest skin score (best response).

Time frame:
Up to Week 36
Reported as:
Number · Days
Time to Progressive Disease Using mSWAT
DaysCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
25th (95% CI)NA (170.0 to NA)191 (85.0 to NA)93 (85.0 to 93.0)
50th (95% CI)NA (NA to NA)NA (NA to NA)93 (NA to NA)
75th (95% CI)NA (NA to NA)NA (NA to NA)93 (NA to NA)
SecondaryChange From Baseline in Skindex-29 Survey Results at Week 12, 24 and 36

Participants answered 30 questions as part of the Skindex-29 survey. A composite score and 3 sub scores were calculated from the results. Item 18 of the survey was not used in any scoring. First, answers to each item were given a numeric value: Never = 0; Rarely = 25; Sometimes = 50; Often = 75; All the time = 100. The items used to calculate each subscore were: Emotions: 3, 6, 9, 12, 13, 15, 21, 23, 26, and 28 (10 items), Symptoms: 1, 7, 10, 16, 19, 24, and 27 (7 items), Functioning: 2, 4, 5, 8, 11, 14, 17, 20, 22, 25, 29, and 30 (12 items). The composite score is the average of the 3 sub scores ranging from 0 (no effect)-100 (maximum effect), higher score corresponds to lower quality of life.

Time frame:
Week 12, 24 and Follow up (Week 36)
Reported as:
Mean · score on scale
Change From Baseline in Skindex-29 Survey Results at Week 12, 24 and 36
score on scaleCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
Week 121.93 ± 12.408-0.27 ± 8.583-1.58 ± 13.243
Week 24-2.16 ± 11.651-3.36 ± 9.8160.58 ± 16.059
Week 36-3.30 ± 14.838-3.22 ± 8.340-0.34 ± 14.081

Adverse events

Collected over From start of the study drug administration up to end of the study (Week 72).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD11301 Gel 0.06%0/30 (0%)2/30 (6.7%)30/30 (100%)
CD11301 Gel 0.03%0/28 (0%)2/28 (7.1%)28/28 (100%)
Placebo1/27 (3.7%)1/27 (3.7%)27/27 (100%)
Most frequent serious events
Most frequent serious events
EventCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/281/27
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/281/27
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/281/27
Metastases to muscleNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/300/281/27
Papillary cystadenoma lymphomatosumNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/301/280/27
Sinus bradycardiaCardiac disorders0/301/280/27
AngioedemaSkin and subcutaneous tissue disorders1/300/280/27
SciaticaNervous system disorders1/300/280/27
Most frequent other events
Showing 10 of 51
Most frequent other events
EventCD11301 Gel 0.06%CD11301 Gel 0.03%Placebo
Application site erosionGeneral disorders9/303/282/27
Application site ulcerGeneral disorders8/308/282/27
Application site pruritusGeneral disorders4/308/284/27
Application site erythemaGeneral disorders7/305/282/27
HeadacheNervous system disorders7/305/281/27
Application site inflammationGeneral disorders0/306/281/27
Application site painGeneral disorders6/303/282/27
Influenza like illnessGeneral disorders6/303/282/27
Mycosis fungoidesNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/304/285/27
PruritusSkin and subcutaneous tissue disorders2/303/285/27

Baseline characteristics

Intent to treat (ITT) Population included all randomized participants.

Age, Continuous
Age, Continuous(years)CD11301 Gel 0.06%CD11301 Gel 0.03%PlaceboTotal
Mean60.4 ± 14.4356.8 ± 15.6861.0 ± 14.2159.5 ± 14.72
Sex: Female, Male
Sex: Female, Male(Participants)CD11301 Gel 0.06%CD11301 Gel 0.03%PlaceboTotal
Female881228
Male22201658
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD11301 Gel 0.06%CD11301 Gel 0.03%PlaceboTotal
Hispanic or Latino1124
Not Hispanic or Latino29272682
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD11301 Gel 0.06%CD11301 Gel 0.03%PlaceboTotal
American Indian or Alaska Native0011
Asian1012
Native Hawaiian or Other Pacific Islander0000
Black or African American0112
White28272479
More than one race0000
Unknown or Not Reported1012
08

Study locations

21 sites
  • Galderma Investigational Site
    Orange, California 92868, United States
  • Galderma Investigational Site
    Palo Alto, California 94304, United States
  • Galderma Investigational Site
    Farmington, Connecticut 06032, United States
  • Galderma Investigational Site
    Chicago, Illinois 60611, United States
  • Galderma Investigational Site
    Boston, Massachusetts 02115, United States
  • Galderma Investigational Site
    Durham, North Carolina 27710, United States
  • Galderma Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Galderma Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Galderma Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Galderma Investigational Site
    Dallas, Texas 75231, United States
  • Galderma Investigational Site
    Houston, Texas 77030, United States
  • Galderma Investigational Site
    Pierre-Bénite, Auvergne-Rhône-Alpes 69310, France
  • Galderma Investigational Site
    Nantes, Pays De La Loire 44093, France
  • Galderma Investigational Site
    Paris, Île-de-France 75010, France
  • Galderma Investigational Site
    Mannheim, Baden-Württemberg 68167, Germany
  • Galderma Investigational Site
    Wurzburg, Bavaria 97080, Germany
  • Galderma Investigational Site
    Krefeld, North Rhine-Westphalia 47805, Germany
  • Galderma Investigational Site
    Minden, North Rhine-Westphalia 32429, Germany
  • Galderma Investigational Site
    Münster, North Rhine-Westphalia 48149, Germany
  • Galderma Investigational Site
    Kiel, Schleswig-Holstein 24105, Germany
  • Galderma Investigational Site
    Berlin, 10117, Germany
09

References and documents

Publications

  • Valipour A, Jager M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD008946. doi: 10.1002/14651858.CD008946.pub3. PubMed 32632956 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No intent to share information.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Mar 2020, 26 months.

Results were first posted in Apr 2021, 1 year after primary completion.

Of 47 phase 2 interventional studies under Lymphoma, T-Cell, Cutaneous, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 97. This study's 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2017
First posted
Sep 25, 2017
StartActual
Dec 19, 2017
Primary completionActual
Mar 17, 2020
CompletionActual
Mar 17, 2020
Results first posted
Apr 8, 2021
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03292406
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Dec 19, 2017
Primary completion
Mar 17, 2020
Completion
Mar 17, 2020
Results posted
Apr 8, 2021
Last update
Apr 8, 2021

Study contacts

Galderma R&D
study director · Galderma R&D

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resiquimod

Start the discussion